lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
=== Absorbability === Aspect ratio affects the ability of the nanocapsule to penetrate tumor cells. Low aspect ratios (spherical capsules) tend to penetrate cells more easily than high aspect ratios (rod-shaped capsules).
Diabetes was diagnosed a few months ago The cat has no other serious disease Treatment includes insulin glargine administered twice daily The cat is monitored frequently during the first few months of treatment The cat eats a diet low in carbohydrates and high in protein. Cats may present with type 2 (insulin-resistant) diabetes, at least at first, but hyperglycemia and amyloidosis, left untreated, will damage the pancreas over time and progress to insulin-dependent diabetes. Glipizide and similar oral diabetic medicines designed for type 2 diabetic humans have been shown to increase amyloid production and amyloidosis and therefore may reduce likelihood of remission. Approximately one-third of cats who achieve remission will later relapse.
== AFL career == Gumbleton's 2007, 2008 and 2009 seasons were all plagued by injury and he played only five AFL games in first three seasons, all of which were in 2007. However, the 2010 season saw much improvement for Gumbleton, having a full pre-season, playing 17 of the first 18 games and being re-signed by Essendon, after showing much improvement. Gumbleton suffered yet another injury in round 18, with broken ribs and a punctured lung, ruling him out for the remainder of the 2010 season. Scott's 2011 season was again plagued by injury and he failed to play any games at AFL level. At the end of 2011 Scott had back surgery to repair a disk. It was hoped the surgery would fix his chronic hamstring issues. In 2012 Scott played his first senior game in nearly two years when he returned against Port Adelaide in round 16, booting three goals. He finished the 2012 season having played six games kicking 11 goals. Despite having long-term offers from rival clubs at the end of 2012 Gumbleton showed his loyalty to Essendon agreeing to a new one-year deal to remain at the club until at least the end of 2013. In October 2013, Gumbleton was recruited by Fremantle, who traded the 55th selection in the 2013 AFL draft to Essendon. After failing to play a senior game in his one season at Fremantle, Gumbleton announced his retirement in September 2014. He returned to Melbourne to play for the Banyule Football Club in the Northern Football League from 2015.
=== CPM, thiol-specific dyes === Alexandrov et al. (2008) published a variation on the Thermofluor assay where SYPRO Orange was replaced by N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM), a compound that only fluoresces after reacting with a nucleophile. CPM has a high preference for thiols over other typical biological nucleophiles and therefore will react with cysteine side chains before others. Cysteines are typically buried in the interior of a folded protein as they are hydrophobic. When a protein denatures cysteine thiols become available and a fluorescent signal can be read from reacted CPM. The excitation and emission wavelengths for reacted CPM are 387 nm/ 463 nm so a fluorescence plate reader or a qPCR machine with specialized filters is required. Alexandrov et al. used the technique successfully on the membrane proteins Apelin GPCR and FAAH as well as β-lactoglobin which fibrillates on heating rather than going to a molten globule.
Sources: en.wikipedia.org
=== Warnings and precautions === In December 2013, the FDA added warnings to the label for clobazam, that it can cause serious skin reactions, Stevens–Johnson syndrome, and toxic epidermal necrolysis, especially in the first eight weeks of treatment.
== Research == Caffeine has been speculated to inhibit paclitaxel-induced apoptosis in colorectal cancer cells. In 2016, in vitro multi-drug resistant mouse tumor cells were treated with paclitaxel encased in exosomes. Doses 98% less than common dosing had the same effect. Also, dye-marked exosomes were able to mark tumor cells, potentially aiding in diagnosis. Aside from its direct clinical use, paclitaxel is also used extensively in biological and biomedical research as a microtubule stabilizer. In general, in vitro assays involving microtubules, such as motility assays, rely on paclitaxel to maintain microtubule integrity in the absence of the various nucleating factors and other stabilizing elements found in the cell. For example, it is used for in vitro tests of drugs that aim to alter the behavior of microtubule motor proteins, or for studies of mutant motor proteins. Paclitaxel has also been used in vitro to inhibit insulin fibrillation. In a molar ratio of 10:1 (insulin:paclitaxel), it hindered insulin fibrillation near 70%. Isothermal titration calorimetry (ITC) findings indicated a spontaneous tendency of paclitaxel to interact with insulin through hydrogen bonds and van der Waals forces. The inhibitory role of paclitaxel is attributed to its impact on the colloidal stability of protein solution, as it was observed that paclitaxel inhibited lysozyme fibrillation by inducing the formation of "off-pathway" oligomeric intermediates, subsequently increasing the colloidal stability. Paclitaxel is sometimes used for in vivo studies as well.
=== Global supply chain and human rights impacts === While domestic debates regarding artificial intelligence in the UK often focus on regulation, copyright, and local labour markets, environmental organisations, human rights groups, and academics have increasingly highlighted the UK's responsibility for the global supply chain impacts of AI. This critique focuses on two primary areas: the environmental and human rights costs of extracting critical minerals for AI hardware, and the exploitation of low-wage "ghost workers" in the Global South for data annotation and content moderation.
Sources: en.wikipedia.org
The therapeutic dosage varies according to the patient's age or clinical condition, but for all treatments with sertraline, it is recommended to start with lower dosages (25 to 50 mg/daily) and adjust according to the patient's therapeutic response, with a maximum maintenance dose of up to 200 mg per day.
== History == 1919 F.D. Edwards establishes Edwards Equipment and Services in London, England. 1939 F.D. Edwards begins manufacturing vacuum equipment. 1955 The company acquires Alto Vuoto SpA, a freeze drying manufacturer in Italy. 1968 The company is acquired by BOC, after staying in private hands through the post-war period and until the 1960s when it went public. 1977 BOC Edwards acquire Kniese Apparatbau GmbH, a freeze drying manufacturer in Germany. 1992 Restructuring of Freeze Drying business resource centralised in Tonawanda (US). 1994 The company’s product portfolio is expanded with the acquisition of pharmaceutical filling systems from Calumatic in The Netherlands. 1995 The company’s portfolio is further expanded with loading systems introduced from the Dongen manufacturing site in The Netherlands. 2004 A joint venture is established with Tianli Cryogenic Company, a pharmaceutical freeze dryer manufacturer in Beijing, China. 2006 The BOC Group is acquired by Linde AG and together form The Linde Group. Linde sells the vacuum division of BOC Edwards. BOC Edwards Pharmaceutical Systems remains part of the Linde Group, as an independent division. 2008 IMA, Italy acquires the BOC Edwards Pharmaceutical Systems group creating IMA Edwards – a part of IMA Life division of the IMA group. 2010 Today the whole group has been renamed under the brand IMA LIFE - Aseptic Processing and Freeze Drying Solutions.
=== Contact process === In 1831, British vinegar merchant Peregrine Phillips patented the contact process, which was a far more economical process for producing sulfur trioxide and concentrated sulfuric acid. Today, nearly all of the world's sulfuric acid is produced using this method. In the early to mid 19th century "vitriol" plants existed, among other places, in Prestonpans in Scotland, Shropshire and the Lagan Valley in County Antrim, Northern Ireland, where it was used as a bleach for linen. Early bleaching of linen was done using lactic acid from sour milk, but this was a slow process; the use of vitriol sped up the bleaching process.
As part of the planning, a force had been placed at Pitsane, on the border of the Transvaal, by the order of Rhodes so as to be able to quickly offer support to the Uitlanders in the uprising. The force was placed under the control of Leander Starr Jameson, the administrator general of the chartered company (of which Cecil Rhodes was the chairman) for Matabeleland. Among the other commanders was Raleigh Grey. The force was around 600 men, about 400 from the Matabeleland Mounted Police and the remainder other volunteers. It was equipped with rifles, somewhere between eight and sixteen Maxim machine guns, and between three and eleven light artillery pieces.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.